



ASX Release Stock Code: PRR

Friday, 30 May 2008

UPDATE ON US FDA pre-IND MEETING FOR CVac™ CANCER TREATMENT

Australian cancer treatment development company Prima BioMed (Prima, the Company) (ASX: PRR) is pleased to announce that it is in the final stages of preparations for a pre-Investigational New Drug Application (pre-IND) meeting with the US Food and Drug Administration (FDA).

Prima aims to secure the grant of an Investigational New Drug Application (IND) by the US FDA for its next clinical trial of CVac™, ovarian cancer treatment, as part of the Company's long term strategic goal of developing commercial cancer treatments.

Prima has been working diligently in recent months on documentation required by the US FDA for its' evaluation of the proposed clinical development strategy for CVac™ and the Company expects to announce details of the pre-IND meeting with the FDA in the near future.

The Board of Prima believes that the pre-IND meeting represents a major step forward in the development of CVac™, and that CVac™'s ongoing development, and ultimate commercialisation if successful, has the potential to add significant value to the Company.

Prima chairman Mr Ata Gokyildirim said that "the Board appreciated the continued support of shareholders throughout this period of preparation for a meeting with the US FDA in respect of the CVac™ cancer treatment".

"A pre-IND meeting with the FDA is a key step in the development of any new therapeutic agent and we are delighted to be in a position to take this milestone step with our CVac™ ovarian cancer treatment, and we look forward to building on this to deliver strong growth for our shareholders," Mr Gokyildirim said.

Ata Gokyildirim
Chairman
Prima Biomed Ltd
Mob: +61 408 685 548
Ph: +61 2 9232 4420

Email: ata@primabiomed.com.au

Website: www.primabiomed.com.au

James Moses
Partner
Fortbridge Consulting

Ph: 0420 991 574

E: james.moses@fortbridge.com

About Prima Biomed Ltd

Prima Biomed (ASX: PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac™ has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.

About CVac™ Ovarian Cancer Treatment

CVac™ is Prima's lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US\$2.1b in 2007 and is expected to total US\$3.6b by 2010.

Regulatory approval for the conduct of further clinical trials of CVac™ over the next 6-9 months is the core focus for Prima.

For further information, visit www.primabiomed.com.au

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Prima BioMed Ltd, Suite 1705, 109 Pitt St, Sydney NSW 2000 AUSTRALIA

www.primabiomed.com.au Ph:+61 2 9232 4420 Fax:+61 2 9232 4450

ABN: 90 009 237 889